Does CONESTAT ALFA Cause Vascular access site complication? 90 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 90 reports of Vascular access site complication have been filed in association with CONESTAT ALFA (Ruconest). This represents 6.0% of all adverse event reports for CONESTAT ALFA.
90
Reports of Vascular access site complication with CONESTAT ALFA
6.0%
of all CONESTAT ALFA reports
0
Deaths
5
Hospitalizations
How Dangerous Is Vascular access site complication From CONESTAT ALFA?
Of the 90 reports, 5 (5.6%) required hospitalization.
Is Vascular access site complication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CONESTAT ALFA. However, 90 reports have been filed with the FAERS database.
What Other Side Effects Does CONESTAT ALFA Cause?
Intentional product use issue (227)
Condition aggravated (166)
Weight fluctuation (125)
Product use in unapproved indication (97)
Drug ineffective (94)
Underdose (74)
Weight decreased (74)
Weight increased (74)
Insurance issue (48)
Product dose omission issue (46)
What Other Drugs Cause Vascular access site complication?
HUMAN C1-ESTERASE INHIBITOR (74)
PEMBROLIZUMAB (14)
CARBOPLATIN (8)
PEMETREXED (7)
ASPIRIN (5)
CLOPIDOGREL BISULFATE (5)
Which CONESTAT ALFA Alternatives Have Lower Vascular access site complication Risk?
CONESTAT ALFA vs COPANLISIB
CONESTAT ALFA vs COPAXONE
CONESTAT ALFA vs COPEGUS
CONESTAT ALFA vs COPPER
CONESTAT ALFA vs CORDARONE